Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130246 · ClinicalTrials.gov registry record · Phase 3
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
A Phase 3 study, sponsored by Anthera Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5,189
- Enrollment target
NCT01130246: Clinical Trial Phase 3 study, sponsored by Anthera Pharmaceuticals.
NCT01130246 is a Phase 3 study that was terminated before completion, run by Anthera Pharmaceuticals. The registered enrollment target is 5,189 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (572% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01130246, a Phase 3 study, was terminated before completion, sponsored by Anthera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5,189 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
Primary Outcome
To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization.
Interventions
- DRUG Placebo
- DRUG A-002, varespladib methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,189 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Why NCT01130246 stopped before completion
NCT01130246 is an interventional study that assigns participants to a tested intervention. Its 5,189 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (572% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01130246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01130246 about?
NCT01130246 is a clinical study titled "VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome". The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
What is the current status of trial NCT01130246?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5,189 participants. The study started on 2010-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01130246?
The interventions under investigation include: Placebo (DRUG), A-002, varespladib methyl (DRUG).
Who is sponsoring clinical trial NCT01130246?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01130246's enrollment target sits among peer trials
5,189 47th of 2000 higher than 1,954 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia